Dadun/></a>
				</td>
				<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Inmunología hepatitis virales > DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista >

Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL)
Authors: Drozdzik, M. (Marek)
Qian, C. (Cheng)
Lasarte, J.J. (Juan José)
Bilbao, R. (Roberto)
Prieto, J. (Jesús)
Keywords: Fas ligand
Tumor
Gene transfer
Animal
Issue Date: 1998
Publisher: Nature Publishing Group
Publisher version: http://www.nature.com/gt/journal/v5/n12/abs/3300763a.html
ISSN: 1476-5462
Citation: Drozdzik M, Qian C, Lasarte JJ, Bilbao R, Prieto J. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL). Gene Ther 1998 Dec;5(12):1622-1630.
Abstract
Fas ligand is a type II transmembrane protein which can induce apoptosis in Fas-expressing cells. Recent reports indicate that expression of FasL in transplanted cells may cause graft rejection and, on the other hand, tumor cells may lose their tumorigenicity when they are engineered to express FasL. These effects could be related to recruitment of neutrophils by FasL with activation of their cytotoxic machinery. In this study we investigated the antitumor effect of allogenic fibroblasts engineered to express FasL. Fibroblasts engineered to express FasL (PA317/FasL) did not exert toxic effects on transformed liver cell line (BNL) or colon cancer cell line (CT26) in vitro, but they could abrogate their tumorigenicity in vivo. Histological examination of the site of implantation of BNL cells mixed with PA317/FasL revealed massive infiltration of polymorphonuclear neutrophils and mononuclear cells. A specific immune protective effect was observed in animals primed with a mixture of BNL or CT26 and PA317/FasL cells. Rechallenge with tumor cells 14 or 100 days after priming resulted in protection of 100 or 50% of animals, respectively. This protective effect was due to CD8+ cells since depletion of CD8+ led to tumor formation. In addition, treatment of pre-established BNL tumors with a subcutaneous injection of BNL and PA317/FasL cell mixture at a distant site caused significant inhibition of tumor growth. These data demonstrate that allogenic cells engineered with FasL are able to abolish tumor growth and induce specific protective immunity when they are mixed with neoplastic cells.
Permanent link: http://hdl.handle.net/10171/21666
Appears in Collections:DA - Medicina - Medicina Interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista

Files in This Item:
File:  GeneTherapy199851622.pdf
Description: 
Size:  793,28 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.